Evidence map›Paper›PMID 39816323›Full record

ReviewCureus2024

Schizophrenia and Bone Marrow Disorders: An Emerging Clinical Association.

Jayalekshmi Jayakumar, Manasa Ginjupalli, Aju Kalaivani Babu, Srinishant Rajarajan, Madhuri Jakkam Setty

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jayalekshmi JayakumarDepartment of Internal Medicine, The Brooklyn Hospital Center, New York, USA.
Manasa GinjupalliDepartment of Internal Medicine, The Brooklyn Hospital Center, New York, USA.
Aju Kalaivani BabuDepartment of Internal Medicine, Allegheny General Hospital, Pittsburgh, USA.
Srinishant RajarajanDepartment of Internal Medicine, Allegheny General Hospital, Pittsburgh, USA.
Madhuri Jakkam SettyDepartment of Psychiatry, Texas Tech University Health Sciences Center, Odessa, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia is a chronic psychiatric disorder with a complex etiology involving genetic, neurobiological, and environmental factors. Many individuals with schizophrenia experience treatment resistance despite advances in pharmacologic and non-pharmacologic interventions. Immune dysregulation, characterized by altered cytokine levels, immune-related gene expression, and neuroinflammation, plays a critical role in schizophrenia's pathogenesis. Furthermore, associations between schizophrenia and bone marrow malignancies, with documentation of remission of treatment-resistant schizophrenia following bone marrow transplantation for malignancies, are emerging. This review synthesizes findings on the immunological underpinnings of schizophrenia, explores potential connections with bone marrow dysfunction, and evaluates the therapeutic potential of immune-modulating approaches, including bone marrow transplantation. By highlighting these connections, the study aims to advance understanding and stimulate prospective research into innovative treatments for this debilitating condition.

Indexed as

bone marrow malignanciesbone marrow transplantationclozapinecytokinesimmune dysregulationneuroinflammationschizophreniaschizophrenia and hematological malignanciestreatment resistant schizophrenia

Identifiers

PMID39816323
PMCPMC11735017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.